KlatzmannD, PhilipponJ, ValeryC, et al.Gene therapy for glioblastoma in adult patients: safety and efficacy evaluation of an in situ injection of recombinant retroviruses producing cells carrying the thymidine kinase gene of the herpes simplex type 1 virus, to be followed with the administration of ganciclovir. Hum Gene Ther, 1996; 7:109–126.
2.
KlatzmannD, HersonS, CherinP, et al.Gene therapy for metastatic malignant melanoma: evaluation of tolerance to intratumoral injection of cells producing recombinant retroviruses carrying the herpes simplex virus type 1 thymidine kinase gene, to be followed by ganciclovir administration. Hum Gene Ther, 1996; 7:255–267.
3.
CulverKW, RamZ, WallbridgeS, et al.In vivo gene transfer with retroviral vector producer cells for treatment of experimental brain tumors. Science, 1992; 256:1550–1552.
4.
CarusoM, PanisY, GagandeepS, et al.Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci U S A, 1993; 90:7024–7028.
5.
GagandeepS, BrewR, GreenB, et al.Prodrug-activated gene therapy: involvement of an immunological component in the “bystander effect.”. Cancer Gene Ther, 1996; 3:83–88.
6.
KianmaneshAR, PerrinH, PanisY, et al.A “distant” bystander effect of suicide gene therapy: regression of nontransduced tumors together with a distant transduced tumor. Hum Gene Ther, 1997; 8:1807–1014.
7.
WeiMX, BougnouxP, Sacré-SalemB, et al.Suicide gene therapy of chemically induced mammary tumor in rat: efficacy and distant bystander effect. Cancer Res, 1998; 58:3529–3532.
8.
Cavazzana-CalvoM, Hacein-BeyS, BasileCD, et al.Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science, 2000; 288:669–672.
9.
KlatzmannD, ChérinP, BensimonG, et al.A Phase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinase “suicide” gene therapy for metastatic melanoma. Hum Gene Ther, 1998; 9:2585–2594.
10.
KlatzmannD, ValéryCA, BensimonG, et al.A Phase I/II study of herpes simplex virus type 1 thymidine kinase “suicide” gene therapy for recurrent glioblastoma. Hum Gene Ther, 1998; 9:2595–2604.
11.
ValéryCA, SeilheanD, BoyerO, et al.Long-term survival after gene therapy for a recurrent glioblastoma. Neurology, 2002; 58:1109–1112.
12.
DalbaC, KlatzmannD, LoggC, et al.Beyond oncolytic virotherapy: replication-competent retrovirus vectors for selective and stable transduction of tumors. Curr Gene Ther, 2005; 5:655–667.
13.
DalbaC, BellierB, KasaharaN, et al.Replication-competent vectors and empty virus-like particles: new retroviral vector designs for cancer gene therapy or vaccines. Mol Ther, 2007; 15:457–466.
14.
WangWJ, TaiCK, KasaharaN, et al.Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors. Hum Gene Ther, 2003; 14:117–127.
15.
SollySK, TrajcevskiS, FrisénC, et al.Replicative retroviral vectors for cancer gene therapy. Cancer Gene Ther, 2003; 10:30–39.
16.
TrajcevskiS, SollySK, FrisénC, et al.Characterization of a semi-replicative gene delivery system allowing propagation of complementary defective retroviral vectors. J Gene Med, 2005; 7:276–287.
17.
CloughesyTF, LandolfiJ, HoganDJ, et al.Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Sci Transl Med, 2016; 8:341ra75.
18.
HuangTT, ParabS, BurnettR, et al.Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model. Hum Gene Ther, 2015; 26:82–93.
19.
SaadounD, RosenzwajgM, JolyF, et al.Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. New Engl J Med, 2011; 365:2067–2077.
20.
KlatzmannD, AbbasAK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol, 2015; 15:283–294.
21.
ChurlaudG, JimenezV, RuberteJ, et al.Sustained stimulation and expansion of Tregs by IL2 control autoimmunity without impairing immune responses to infection, vaccination and cancer. Clin Immunol, 2014; 151:114–126.
22.
AlvesS, ChurlaudG, AudrainM, et al.Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer's disease mice. Brain, 2017; 140:826–842.
